Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to ...

Plus: Why Krispy Kreme left McDonald's, Boeing's latest woes, the potential Shell-BP merger, Bumble's stumble, Nvidia's cloud ...

Compulsive hoarders feel stigmatized and are more likely to view their neighborhoods as less safe and more chaotic than ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Hims & Hers' (NYSE: HIMS) stock crashed over 30% following news highlighting the end of its relationship with Novo Nordisk ...

STORY: Novo Nordisk is to collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy.Under the deal to ...

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.1% in the afternoon session after the company's CEO ...

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

On Monday, Novo Nordisk, the producer of the popular weight loss drug, Wegovy, announced that it was ending its partnership with virtual healthcare provider Hims & Hers, and the market didn't like ...